Macropore biosurgery: Charttechnischer Kauf

mit solchen Fangfragen aufs Glatteis locken?

Nicht mit mir!




Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

Keine Ahnung ob das im Freiverkehr weitergeht und auf L&S. Ob der Übertrag nach USA kostenfrei gemacht wird?

Dear Friends and Investors,

Cytori Therapeutics (NASDAQ: CYTX; Frankfurt: XMPA) is voluntarily delisting from the Frankfurt Stock Exchange (FSE). The move is primarily in response to the significant shift in trading volume since December 2005 from the FSE toward the NASDAQ Global Market, where Cytori will maintain its primary listing. Cytori's last day of trading on the FSE will be September 25, 2007. Following this date, shares owned in Germany, the United States, or elsewhere may continue to be traded through the NASDAQ Global Market under the symbol CYTX.

"This is an opportunity to consolidate trading on one of the most efficient international stock markets, the NASDAQ Global Market, where the vast majority of our shares now trade, while simultaneously reducing redundant fees and expenses associated with a dual listing," said Mark Saad, Chief Financial Officer for Cytori. "All our shareholders will be optimally supported by the single listing and the European investment community will continue to be a priority for us, given our global reach as a regenerative medicine company."

Investors, brokers and other shareholder representatives are encouraged to contact Cytori's investor relations department directly with any questions at 858-458-0900.

Regards,

Cytori Therapeutics

Contact:

Tom Baker
Tel. 858-875-5258
tbaker@cytoritx.com  

 

News & Analysis: Biotech	<!--The Page Area is EMPTY-->

Three Stem-Cell Stocks Ripe With Potential By Melissa Davis Senior Writer 6/26/2007 7:12 AM EDT Click here for more stories by Melissa Davis

Investing in biotechnology companies is said to be like playing the slots, but hitting the jackpot can be even harder with stem-cell stocks.

Take Geron (GERN - Cramer's Take - Stockpickr - Rating), the worldwide leader in embryonic stem-cell research. It might very well cure cancer and paralysis one of these days. But the company has cost investors plenty, with its stock spiraling from $75 to $8 a share this decade.

But after researching the stem-cell industry for more than 10 years, WBB Securities analyst Stephen Brozak finally sees some payoffs on the horizon. Brozak believes that Geron's day will come and says some smaller players with commercial products on the way could bring more immediate rewards.

Brozak points to Cytori (CYTX - Cramer's Take - Stockpickr - Rating), a stem-cell company about to introduce a new medical device, as his favorite pick. Cytori's stock, down 7 cents to $5.67 Friday, trades near the middle of its 52-week range.

"If you want to make a play for stem cells here and now, you have to look at Cytori," insists Brozak, whose firm has provided consulting services to the company in the past. "We believe that they will have the first meaningful stem-cell application."

That product, a medical device that makes use of stem cells extracted from a patient's own fat, could earn regulatory approval later this year. It represents a novel breakthrough for patients undergoing breast surgery and, down the road, could bring relief to huge numbers of patients suffering from heart damage as well.

Meanwhile, Brozak stresses the importance of stock selection in the group.

"We've singled out companies with competitive advantages and significant partnerships that validate their franchises," says Brozak, whose firm has no position in stem-cell stocks themselves. In the end, "this is just as much an art as it is a science."

To watch Alix Steel's video take of this column, click here.

 

Page 1 2 3 4 NEXT PAGE >

Zum Rest:

http://www.thestreet.com/_yahoo/newsanalysis/...at=FREE&cm_ite=NA

 

Cytori Looks for Fat Profits

By Melissa Davis
Senior Writer
6/26/2007 7:14 AM EDT
Click here for more stories by Melissa Davis

The stem cell industry is known for making big promises. But the pledge made by Cytori (CYTX - Cramer's Take - Stockpickr - Rating) -- an obscure name in this sometimes overhyped field -- really stands out.
"Our goal is to be not only one of the first revenue-generating stem cell companies but also to be the first profitable one," says Cytori CEO Christopher Calhoun. "It's something we're targeting to do sooner rather than later. ... You won't hear that from others."

To be sure, Cytori seems to face a shorter path than most. As rival stem cell players, such as Geron (GERN - Cramer's Take - Stockpickr - Rating), pursue new drugs that could be years -- if not decades -- away, Cytori is seeking near-term approval of its own products through the less arduous process established for medical devices. The company hopes to secure regulatory permission to start selling its first breakthrough treatment, involving stem cells extracted from a patient's own fat, by the end of this year.

Cytori has invented a device that can withdraw stem cells from patient fat for re-use elsewhere in the body. The entire process takes around an hour and, at $2,500 to $10,000 per treatment, looks downright cheap for stem cell-based therapy.

Still, Cytori plans to dominate its first market by addressing an unmet need. If all goes as planned, the company will soon roll out a novel treatment for breast cancer patients seeking reconstructive surgery following partial mastectomies -- or lumpectomies -- that remove tumors but spare the rest of the breast. Those partial breast removals currently leave patients with scars, radiation damage and other reminders of their cancer.


Page 1 2 3 4 NEXT PAGE >

Rest hier:

http://www.thestreet.com/_yahoo/newsanalysis/...cm_cat=FREE&cm_ite=NA  

schade, zumal bei der Rolle, die Cytori spielen will, das Listing in europa Pflicht ist. gibt es hierzu evtl. Neuigkeiten?
Ich überlege, vorher nochmal Gebühren-günstiger aufzustocken.  

Berichtspflicht speziell für Deutschland ein.
Handel in Frankfurt, München oder Stuttgart geht weiter. Es soll sogar am Nachmittag auf Nasdaqkurse gemakelt werden in Berlin oder so.
Weiß ich aber nicht so genau.  

Url: http://www.focus.de/gesundheit/ratgeber/krebs/news/brustaufbau_aid_65886.html09.07.07, 09:06Drucken
  

Brustaufbau

Neuer Busen durch Fettstammzellen

Stammzellen aus dem Fettgewebe lassen nach einer Brustkrebs-OP den Busen nachwachsen. Auch kranken Herzen könnte das neue Verfahren helfen.Allein in Europa muss jährlich rund 180 000 Frauen ein Teil der Brust entfernt werdenKunstbrüste aus Silikon könnten bald der Vergangenheit angehören. Mit einem neuen Verfahren haben Wissenschaftler zumindest Brustkrebspatientinnen einen neuen Busen wachsen lassen. Die 19 Teilnehmerinnen der klinischen Studie aus Japan hatten im Rahmen einer Brustkrebsbehandlung Teile ihres Busens eingebüßt.

Für ihren Versuch entnahmen Mediziner den Frauen Fettgewebe aus dem Po oder dem Bauch. In nur einer Stunde isolierten sie daraus Stammzellen und reicherten sie anschließend an. In die Brustregion injiziert, ließen die multipotenten Zellen innerhalb von sechs Monaten neues Brustgewebe sprießen.

Neue Blutgefäße fördern das Gewebewachstum

Auf welche Weise das Verfahren funktioniert, ist noch unklar. Die Forscher vermuten aber, dass die Stammzellen das Wachstum neuer Blutgefäße anregen, was die Neubildung von Gewebe fördert. Neben dem Busen ließen sich mit der Methode auch andere Körperpartien aufpolstern.

Das kalifornische Biotechnologieunternehmen Cytori Therapeutics, das das System unter dem Namen Celution auf den Markt bringt, hat in Deutschland bereits eine Zulassung erhalten. Die Markteinführung ist für das Frühjahr 2008 geplant. Allein in Europa erkranken alljährlich rund 300 000 Frauen an Brustkrebs. 60 Prozent von ihnen wird ein Teil der betroffenen Brust entfernt.

Fettstammzellen auch fürs Herz?

In weiteren Studien wollen die Forscher untersuchen, ob die Methode für die Reparatur von Herzgewebe taugt. Nachdem Versuche an Tieren mit einer Herzerkrankung vielversprechend verliefen, sollen in einem spanischen Krankenhaus Patienten mit verengten Herzkranzgefäßen mit Stammzellen aus Fettgewebe behandelt werden. In einem niederländischen Krankenhaus ist eine Studie mit Patienten geplant, die eine Herzattacke hatten.

 

Schon erstaunlich. Alle Stammzellenfirmen sind weit in der Forschungsphase. Nur Cytori will 2008 die Markteinführung. Und der Kurs geht immer noch nicht ab.  

Oder alle aufm Mars zurück?  

Hatte vor einiger Zeit mein deutsches Konto geräumt und dafür in den USA nachgekauft.
Als ob ich das mit dem Delisting geahnt hätte :-)

Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

als bei mancher Bio-Wert.  

Korrektur: bei manchem Bio-... Das gibt glaub ich schnelleres Geld als anderswo im Bio, ausser jetzt aktuell GPC. Bin guter Zuversicht, was ist Dein Statemant?  

ist stark runtergekommen, aber keiner mach ab 2008 Umsatz. Ich denke irgendwann die nächsten Monate startet eine schöne Bewegung.

6,50 bis 6,70 ist die entscheidende Hürde.

Übrigens: In Deutschland wird nur Xetra abgeschafft (eingespart) und die Berichtspflicht extra nach deutschen Regeln. Auf den Börsen von Frankfurt, Berlin und sonstwo kann man Cytori weiter handeln,  und besonders liquide war es hier eh noch nie....  

Der wievielte Anlauf war das jetzt?



Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

null  

14.08.2007 14:57

Cytori Therapeutics and Green Hospital Supply to Commercialize Celution(TM) System in Japan

Cytori Therapeutics (Nachrichten/Aktienkurs) (NASDAQ:CYTX) (Frankfurt:XMPA) and Green Hospital Supply, Inc. (TYO:3360), have partnered to commercialize Cytori's StemSourceâ„¢ cell bank, which includes Cytori's Celutionâ„¢ System, to hospitals throughout Japan. The partnership marks the first commercial introduction of the Celutionâ„¢ System and will target a market opportunity estimated at more than $1 billion. “Our StemSourceâ„¢ cell bank is a comprehensive automated platform that incorporates the Celutionâ„¢ System and related disposables to provide a turnkey stem and regenerative cell banking operation for almost any hospital or clinic in Japan,“ said Christopher J. Calhoun, CEO, Cytori Therapeutics. Under the agreement, Green Hospital Supply will be the exclusive Japanese provider of both the StemSourceâ„¢ banking platform and the Celutionâ„¢ System for stem and regenerative cell banking. Cytori retains exclusive rights for both products in other countries. Revenues from all related product sales will be shared equally between Cytori and Green Hospital Supply. “Stem cell banking is an underserved market in Japan, which is the second largest medical market in the world,“ said Kunihisa Furukawa, President, Green Hospital Supply. “Cytori's products coupled with Green Hospital Supply's market leadership in the supply, outfitting and management of more than 350 Japanese hospitals, makes this a compelling opportunity for both companies. We intend to begin introduction of these products by the first quarter of 2008, with a goal of installing cell banks in 250 hospitals by 2011.“ StemSourceâ„¢ Cell Bank The StemSourceâ„¢ cell bank, which features Cytori's Celutionâ„¢ System, is designed to enable hospitals and clinics to become regenerative medicine centers able to remove, process, retrieve and store regenerative cells from a patient's adipose tissue. Once installed, the cell bank may be offered as an add-on banking procedure for hospital-admitted patients and in conjunction with surgeries. Adipose Regenerative Cells Adipose tissue is a rich and easily accessible source of stem and regenerative cells believed to be involved in the healing process. Scientific data shows that as the body ages, so too do one's regenerative cells. For this reason, early cell retrieval and storage may enhance their therapeutic potential. Management Discussion Cytori will webcast an investor conference call today at 10 a.m. Eastern Daylight Time, in conjunction with the previously scheduled second quarter financial results conference call, to discuss the transaction. The webcast may be accessed at www.cytoritx.com. Green Hospital Supply, Inc. Green Hospital Supply, Inc. (TYO:3360) operates four businesses, which offer one-stop solutions for medical institutions in Japan to optimize their hospital management. The Total Pack System business offers solutions to meet the needs of clients to open, relocate, add and/or renovate hospital facilities. Green Hospital Supply continues the client relationships by selling medical practice materials and consumables after hospitals start operations (Medical Supply Business), and supplying meals and medical-related services (Health Care Business). The Company strengthens ties with its clients by making them business partners to further expand the spectrum of businesses, for example, launching dispensing pharmacies near hospitals (Health Care Business). www.ghs-inc.co.jp Cytori Therapeutics Cytori Therapeutics is a global leader in the development and commercialization of regenerative medicine products. The company is developing therapeutic applications for its Celutionâ„¢ System to enable real-time regenerative cell therapy in conjunction with breast reconstruction surgery, cardiovascular disease, and other unmet medical needs. The Company's StemSourceâ„¢ Cell Bank, which is based on Cytori's innovative Celutionâ„¢ System, is being commercialized in Japan to hospitals and clinics to enable regenerative cell banking. www.cytoritx.com. Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

 

Beginnend ab Q1 208. :-))  

Langsam fall ich echt vom Glauben ab.

Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

abgeben. Als so ziemlich einziger Wert meiner WL.

Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

vielleicht ein mars.  

Cytori Therapeutics CEO Sells Shares
Monday August 27, 10:55 am ET
Cytori Therapeutics CEO Christopher J. Calhoun Sells 50,000 Shares

NEW YORK (AP) -- The chief executive of Cytori Therapeutics Inc., which develops stem cell-based therapies, sold 50,000 shares of common stock, according to a Securities and Exchange Commission filing.

In a Form 4 filed with the SEC Friday, Christopher J. Calhoun reported he sold the shares Wednesday for $5.20 to $5.40 apiece.



Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

ir.cytoritx.com/shareholder_letter/cytori_shareholder_letter.cfm

 

Dear Shareholders:

It is with great enthusiasm that I share our recent achievements and near term goals. We are at an exciting inflection point - the commercial introduction of our Celution™ System for two major applications: reconstructive surgery and stem cell banking.

The Celution™ System was designed as a bedside device to separate and concentrate a patient's own stem and regenerative cells trapped within fat tissue so they may be re-administered in the same procedure. The commercial model will be based on system sales and recurring revenue from single-use, per-procedure consumables.

We encourage investors to measure Cytori's performance based on our achievement of the following near term milestones:

• Market introduction of the Celution™ System for plastic and reconstructive surgery in Europe
• Install the first Celution™ System-based StemSource Cell Banks in Japan
• Initiate a multi-center breast reconstruction study in Europe in patients following partial mastectomy
• Report the outcome of an investigator-initiated breast reconstruction safety and feasibility study in Japan
• Expand the Celution™ System development pipeline with initiation of a clinical trial in heart attack patients
• Complete enrollment of our chronic heart disease clinical trial, a major part of our development pipeline

Two Planned Market Introductions in Early 2008

 

usw......

 

 

Noch ein Auszug aus dem Aktionärsbrief:

Outlook

2007 is an exciting year for Cytori as we have already met many of our milestones and have several more important value driving achievements coming. We are making substantial progress across many fronts that bring the company closer to   commercialization and fulfilling our goal of becoming the leading and first profitable stem cell and regenerative medicine company.

Thanks to all of our employees for their dedication, and thank you to our partners and shareholders for your continued confidence and participation in our growth.

xxxxxxxxxxxxxxx

Sonst liest es ja gar keiner. Und der Kurs gestern spiegelt die BE-Ankündigung:

 

Noch ist es nur ein Ziel  - wenn es irgendwann soweit sein sollte, wird das kurstechnisch ganz anders gewürdigt.
Diesen Anstieg hatten wir doch jetzt schon etliche male, da gebe ich erstmal gar nichts drauf.
Wenn die 6.50 mal nachhaltig geknackt ist, können wir uns weiter unterhalten.

Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst  

Chart öffnen
Über 6,65 sollten es schon werden für langfristige Signale.....

Vorher kann man aber schon mitschwimmen.

xxxxxxxxxxxxxxx

Lars, magst du nicht mal einen cytori-Thread aufmachen, damit das auch in der Überschrift steht?